Department of radiation oncology, Institut Curie, Paris, France.
Department of radiation oncology, Institut Curie, Paris, France.
Cancer Radiother. 2021 Jun;25(4):358-365. doi: 10.1016/j.canrad.2021.01.005. Epub 2021 Mar 3.
Breast protontherapy efficiently limits cardiac, lung and contralateral breast exposure, which may clinically translate into better late tolerance profile compared with classic photon techniques. While breast protontherapy is already implemented in the United States and in some European countries, clinical experience of breast cancer protontherapy is currently limited in France. The aim of this study is to evaluate the clinical practice of breast cancer protontherapy at the Institut Curie in order to implement this technique at a larger scale.
Data from all breast cancer patients that have been addressed to the protontherapy centre of Orsay (CPO, Institut Curie) for adjuvant breast protontherapy were retrieved. We analysed why these patients were ultimately treated with protontherapy or not.
Between November 2019 and November 2020, eleven breast cancer patients have been evaluated for adjuvant protontherapy at the CPO. Two of them were ultimately treated with proton beams; adjuvant breast protontherapy therapy was well tolerated. The nine other patients were not treated with protontherapy due to lack of availability of protontherapy treatment rooms in acceptable time limits, at the time of patient evaluation.
Despite dosimetric advantages and excellent clinical tolerance, lack of availability of protontherapy machines currently limits wider implementation of breast protontherapy.
乳腺质子治疗能有效地限制心脏、肺和对侧乳房的照射，这可能会在临床上转化为更好的晚期耐受。虽然乳腺质子治疗已经在美国和一些欧洲国家实施，但在法国，乳腺癌质子治疗的临床经验目前仍然有限。本研究的目的是评估居里研究所（Institut Curie）乳腺癌质子治疗的临床实践，以便在更大范围内实施这种技术。
检索了所有在奥赛质子治疗中心（CPO，居里研究所）接受辅助乳腺质子治疗的乳腺癌患者的数据。我们分析了为什么这些患者最终接受了质子治疗或没有接受质子治疗。
2019 年 11 月至 2020 年 11 月，11 名乳腺癌患者在 CPO 接受了辅助质子治疗的评估。其中 2 名患者最终接受了质子束治疗；辅助乳腺质子治疗耐受性良好。其他 9 名患者由于在患者评估时无法在可接受的时间范围内获得质子治疗室，因此未接受质子治疗。
尽管具有剂量学优势和良好的临床耐受性，但质子治疗机的缺乏目前限制了乳腺质子治疗的广泛应用。
